30 results on '"Hembrough, Todd"'
Search Results
2. MET inhibitor resistance in patients with MET exon 14-altered lung cancers.
3. Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
4. Identifying treatment options for SCLC patients with multiplexed clinical proteomic testing.
5. Comprehensive proteomic and genomic profiling to identify therapeutic targets in adenoid cystic carcinoma.
6. DESMOPAZ pazopanib (PZ) versus IV methotrexate/vinblastine (MV) in adult patients with progressive desmoid tumors (DT) a randomized phase II study from the French Sarcoma Group.
7. Predicting pathological complete response (pCR) to neoadjuvant trastuzumab in patients with breast cancer using HER2 mass spectrometry.
8. The prognostic role of microsatellite status, tumor mutational burden, and protein expression in CRC.
9. Selecting patients with stage II/III colorectal cancer for 5-fluorouracil-based adjuvant chemotherapy using proteomic analysis.
10. Selecting patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of MGMT.
11. Investigating tumoral and temporal heterogeneity through comprehensive -omics profiling in patients with metastatic triple negative breast cancer.
12. Predicting survival in gastric cancer patients randomized to docetaxel with mass spectrometric quantitation of TUBB3.
13. Quantitative proteomic analysis of TUBB3 to identify gastric cancer patients who may benefit from docetaxel: A reevaluation of the ITACA-S trial.
14. Economic impact and outcome benefits of integrating quantitative proteomics analysis to guide treatment strategies for metastatic breast cancer patients.
15. KRAS gene amplification to define a distinct molecular subgroup of gastroesophageal adenocarcinoma.
16. Use of next generation sequencing and quantitative mass spectrometry to determine HER2 status.
17. KRAS gene amplification to define a distinct molecular subgroup of gastroesophageal adenocarcinoma.
18. Proteomic analysis of primary and metastatic breast cancers and expression of the folate receptor as a potential drug target.
19. Genomics, transcriptomics, and proteomics in the clinical setting: Integrating whole genome and RNA sequencing with quantitative proteomics to better inform clinical treatment selection.
20. Clinical implication of mass-spectrometry-based selected reaction monitoring (SRM) assay in non-small cell lung cancer (NSCLC) patients exhibiting ALK gene rearrangement.
21. Quantitative measurement of HER2 levels by multiplexed mass spectrometry to predict survival in gastric cancer patients treated with trastuzumab.
22. HER2 quantification by mass spectrometry compared to IHC or ISH in predicting clinical benefit from anti-HER2 therapy in HER2-positive breast cancer (BC).
23. Her2 expression in gastroesophageal cancer (GEC) FFPE tissue using mass spectrometry (MS) and correlation with HER2 gene amplification.
24. Correlation of high levels of HER2 measured by multiplex mass spectrometry with increased overall survival in patients treated with anti-HER2-based therapy.
25. Escape of EML4-ALK NSCLC to early phase precision therapy through TGFβ2-HOX-bioenergetics reprogramming.
26. Toward personalized treatment for gastroesophageal adenocarcinoma (GEC): Strategies to address tumor heterogeneity—PANGEA.
27. Quantification of MET expression using mass spectrometry (MS): Assay precision and stability in FFPE tumor tissue.
28. Quantification of HER2 from gastroesophageal cancer (GEC) FFPE tissue by mass spectrometry (MS).
29. Development and clinical validation of an adeno/squamous multiplexed diagnostic assay for NSCLC.
30. Multiplexed mass spectometic quantitation of HER1-3, cMET, and IGF1R in FFPE tumor samples: Implications for targeted therapy and resistance.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.